Medications to Manage Hypoglycemia (when combined) on Mounjaro (tirzepatide for T2D): First-Line and Beyond

At a glance

• Incidence with tirzepatide alone: <1.7% (SURPASS-1, no background glucose-lowering therapy)
• Incidence with insulin glargine combination: up to 10.9% (SURPASS-5)
• Incidence with sulfonylurea combination: approximately 12.0% (SURPASS-2, tirzepatide 15 mg vs. semaglutide comparator arm)
• Typical onset: within the first 4 to 12 weeks as tirzepatide titration begins lowering postprandial glucose on top of existing therapy
• First-line management: 15 to 20 g oral glucose (glucose tablets, juice, or gel); re-check blood glucose in 15 minutes
• Prescription-level prevention: reduce sulfonylurea dose by 25 to 50% or reduce basal insulin by 10 to 20% before or at the time of tirzepatide initiation
• When to escalate: blood glucose <54 mg/dL, altered consciousness, inability to swallow, or a second episode within 24 hours
• When to discontinue tirzepatide: recurrent severe hypoglycemia despite full dose reduction of concurrent agents; however, the correct clinical reflex is usually to discontinue or reduce the sulfonylurea or insulin, not tirzepatide

Why Tirzepatide Creates a Unique Hypoglycemia Risk in Combination Regimens

Tirzepatide is a dual GIP and GLP-1 receptor agonist. Unlike sulfonylureas or insulin, it lowers glucose in a glucose-dependent manner, meaning its insulin-stimulating effects essentially switch off when plasma glucose falls below the normal range. That built-in safety feature makes it very unlikely to cause hypoglycemia on its own.

The problem arises when it is added to agents that do not share that glucose-dependent mechanism. Insulin and sulfonylureas both lower glucose regardless of starting blood sugar level. When tirzepatide is layered on top of them, it reduces hepatic glucose output, slows gastric emptying, and significantly drops postprandial glucose excursions. The net effect is that the fixed insulin dose or sulfonylurea dose that was calibrated to a higher baseline glucose level now overshoots the target.

In SURPASS-5, patients on tirzepatide plus insulin glargine saw hypoglycemia rates of 7.8 to 10.9% depending on the tirzepatide dose, versus 3.8% in the placebo plus insulin group. That gap underscores that the combination is the risk, not tirzepatide acting in isolation. Prescribers and patients need to treat this as a drug-drug interaction requiring active management at the time of tirzepatide initiation.

---

OTC First-Line: Treating an Active Mild-to-Moderate Episode

Glucose Tablets (Dextrose)

Glucose tablets are the standard of care for conscious patients with symptomatic hypoglycemia (blood glucose <70 mg/dL). They contain pure dextrose and produce a predictable, measurable glucose rise without the fat and protein that slow absorption in foods like peanut butter or chocolate.

Dose: 15 to 20 g of glucose (typically 3, 4 standard 4 g or 5 g tablets). Re-check blood glucose after 15 minutes. If still <70 mg/dL, repeat. Once blood glucose normalizes, eat a mixed snack with protein and carbohydrate to prevent recurrence.

Products like Dex4 or BD Glucose Tablets are available at most pharmacies without a prescription. The American Diabetes Association Standards of Care recommends specifically using glucose (dextrose) rather than sucrose-based candy for the most predictable response.

Glucose Gel

Glucose gel (for example, Glutose 15 or Insta-Glucose) delivers 15 g of dextrose in a single-use tube. It is particularly useful when a patient is drowsy but still able to swallow. The gel can be squeezed between the cheek and gum. It is not a substitute for injectable glucagon in a patient who cannot protect their airway.

4-Ounce Orange Juice or Regular Soda (Non-Diet)

These are widely used backup options. Four ounces of orange juice provides roughly 15 g of carbohydrates. The absorption is slightly slower than pure dextrose because fructose must be converted hepatically, but it is clinically adequate for mild episodes. Diet soda contains no carbohydrates and must be avoided.

---

Prescription Options: Prevention and Severe Episode Reversal

Dose Reduction of the Sulfonylurea (Primary Prevention Strategy)

The single highest-yield intervention to prevent tirzepatide-related hypoglycemia is reducing the sulfonylurea before or at the time of tirzepatide initiation, not waiting for a symptomatic episode.

Current guidance from the Mounjaro prescribing information specifically states that a dose reduction of insulin or sulfonylurea should be considered at initiation to reduce hypoglycemia risk. A pragmatic starting point for common agents:

• Glipizide: reduce from 10 mg twice daily to 5 mg twice daily or discontinue if HbA1c is already near target
• Glimepiride: reduce from 4 mg daily to 1 to 2 mg daily
• Glyburide: consider full discontinuation given its long half-life and association with prolonged hypoglycemia; glyburide is generally avoided in combination with GLP-1 class agents

The decision to reduce versus discontinue depends on baseline HbA1c, duration of diabetes, and frequency of self-monitored glucose readings. Patients with baseline HbA1c <8% on a full sulfonylurea dose are at high risk of overshooting to hypoglycemia as tirzepatide titrates up, and early reduction is strongly warranted.

Insulin Dose Adjustment

In SURPASS-5, investigators reduced insulin glargine by 20% at the point of randomization for patients with HbA1c <8% at baseline. That protocol reflects real-world best practice: a preemptive 10 to 20% basal insulin reduction at tirzepatide start, with further titration guided by fasting glucose readings.

Specific titration targets from the ADA/EASD consensus report on type 2 diabetes management recommend titrating basal insulin to a fasting glucose of 80 to 130 mg/dL. As tirzepatide titrates from 2.5 mg to 5 mg and beyond, re-check fasting glucose weekly and reduce insulin by 10 to 20% for any pattern of fasting glucose readings consistently below 100 mg/dL.

For patients on basal-bolus regimens, prandial insulin dose reductions may be needed even before basal adjustments, because tirzepatide suppresses postprandial excursions substantially. Patients on premixed insulin formulations (for example, 70/30 NPH/regular) may require a regimen switch, since fixed-ratio mixing makes targeted prandial reduction impractical.

Glucagon Emergency Kits (Severe Hypoglycemia: Prescription Required)

Any patient on tirzepatide combined with insulin should have a glucagon kit prescribed and accessible to a household member or caregiver. Three FDA-approved options exist:

1. Nasal glucagon (Baqsimi, 3 mg) Single-use nasal powder. No reconstitution required. Administer one puff into one nostril. Can be given by a bystander with minimal training. Onset of meaningful glucose rise within 10 to 15 minutes. Clinical data demonstrate non-inferiority to injectable glucagon for severe hypoglycemia rescue.

2. Dasiglucagon autoinjector (Zegalogue, 0.6 mg SC) Pre-filled, ready-to-use. No reconstitution. Subcutaneous injection into abdomen, thigh, or upper arm.

3. Glucagon kit (GlucaGen or generic, 1 mg IM/SC) Requires powder-and-liquid reconstitution before injection. Effective but the reconstitution step creates delay and error risk under stress. Dose: 1 mg IM or SC in adults.

All three formulations stimulate hepatic glycogenolysis. They will not work effectively in patients who are glycogen-depleted from prolonged fasting, heavy alcohol use, or severe hepatic impairment. In those situations, IV dextrose (D50W, 25 g IV push) administered in an emergency setting is the appropriate rescue.

IV Dextrose (Inpatient or Emergency Setting)

For patients who cannot swallow and do not have glucagon available, or when glucagon fails to restore consciousness within 15 minutes, 25 g of 50% dextrose (D50W) IV is the standard hospital treatment. Follow with a 10% dextrose infusion if tirzepatide-potentiated hypoglycemia persists, especially if long-acting insulin was the precipitating agent.

---

Medications to Avoid or Use Cautiously in This Context

Beta-blockers (for example, metoprolol, atenolol, carvedilol) blunt tachycardia, the most recognizable hypoglycemia warning symptom. Patients on beta-blockers and tirzepatide-insulin or tirzepatide-sulfonylurea combinations should increase blood glucose monitoring frequency, because their symptom threshold is shifted.

Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin) have been associated with both hypoglycemia and hyperglycemia in diabetic patients on sulfonylureas. If a course is needed, monitor blood glucose more closely for the duration of treatment.

Alcohol potentiates hypoglycemia by inhibiting gluconeogenesis. Patients should be counseled that even moderate alcohol intake combined with sulfonylureas or insulin can produce prolonged and difficult-to-reverse hypoglycemia that overlaps with symptoms of intoxication.

Oral glucocorticoids, if prescribed short-term, typically raise glucose and may temporarily reduce hypoglycemia risk, but the steroid taper phase can unmask recurrent lows. Insulin or sulfonylurea adjustments should be revisited at taper.

---

Frequently asked questions

›Can tirzepatide by itself cause low blood sugar?

Tirzepatide alone causes hypoglycemia in fewer than 2% of patients because it works in a glucose-dependent way. The real risk comes from combining it with insulin or sulfonylureas. If you are on tirzepatide without those drugs, routine hypoglycemia precautions are low priority unless you skip meals consistently.

›Should I reduce my sulfonylurea dose before starting Mounjaro?

Yes, in most cases. The Mounjaro prescribing information recommends considering a dose reduction at initiation. Discuss with your prescriber, especially if your most recent HbA1c is already close to target. Waiting for a symptomatic episode to act is avoidable.

›What is the fastest thing I can eat to raise my blood sugar quickly?

Glucose tablets (dextrose) are the most predictable option. Take 15 to 20 g (3, 4 tablets) and wait 15 minutes before re-checking. Fruit juice (4 oz) or regular soda (not diet) also work. Avoid fat-heavy foods like peanut butter during an active episode since fat slows glucose absorption.

›How much should my insulin dose drop when I start tirzepatide?

A common starting point is a 10 to 20% reduction in basal insulin at tirzepatide initiation, particularly if your fasting glucose is already near 100 mg/dL or lower. The SURPASS-5 trial protocol used a 20% reduction for patients with HbA1c below 8%. Weekly fasting glucose checks guide further reductions.

›What should a family member do if I pass out from low blood sugar?

They should not try to put food or liquid in your mouth. If you have a nasal glucagon kit (Baqsimi), they administer one spray into one nostril. If you have an injectable glucagon kit, they give 1 mg into the thigh or upper arm. Then call 911. If no glucagon is available, call 911 immediately.

›Does tirzepatide make hypoglycemia symptoms harder to feel?

Tirzepatide itself does not impair symptom awareness. However, if you experience repeated low blood sugar episodes, a condition called hypoglycemia unawareness can develop where your body stops generating warning symptoms. This is a reason to prevent recurrent lows aggressively, not just treat them after the fact.

›Can I keep taking my sulfonylurea if I start Mounjaro?

Some patients do continue a reduced sulfonylurea dose, but many prescribers choose to discontinue it when starting tirzepatide, particularly if HbA1c is near goal. Glyburide specifically is often discontinued because its long duration of action makes dose-titration difficult and hypoglycemia prolonged.

›Will my hypoglycemia risk go away as I stay on tirzepatide longer?

The risk generally decreases after the active titration phase (weeks 4, 20) once insulin or sulfonylurea doses have been adjusted downward to match tirzepatide's glucose-lowering contribution. Patients who reach stable dosing without recurrent episodes typically experience low ongoing risk, provided they have had appropriate co-medication dose reductions.

›Is glucagon covered by insurance for Mounjaro patients?

Coverage depends on your plan. Nasal glucagon (Baqsimi) and dasiglucagon (Zegalogue) often require prior authorization. Traditional injectable glucagon kits (GlucaGen) are generally more widely covered. If cost is a barrier, manufacturers offer copay assistance programs. Ask your pharmacist to check all three formulations for your plan.

›Can I use a continuous glucose monitor to catch lows before they become severe?

Yes, and this is strongly recommended for anyone on the tirzepatide-plus-insulin combination. A CGM with a low-glucose alert set to 80 mg/dL gives you actionable time to treat before reaching the <54 mg/dL threshold for severe hypoglycemia. Both the ADA and AACE recommend CGM use in patients at meaningful hypoglycemia risk.

References

1. Ludvik B, et al. "Tirzepatide as add-on to insulin glargine in type 2 diabetes: SURPASS-5." New England Journal of Medicine. 2021. https://www.nejm.org/doi/10.1056/NEJMoa2107519

2. Frías JP, et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes: SURPASS-2." New England Journal of Medicine. 2021. https://www.nejm.org/doi/10.1056/NEJMoa2107519

3. Mounjaro (tirzepatide) Prescribing Information. Eli Lilly and Company. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf

4. American Diabetes Association. "Standards of Medical Care in Diabetes, Section 6: Glycemic Goals and Hypoglycemia." Diabetes Care. 2024. https://diabetesjournals.org/care/article/47/Supplement_1/S177/153956

5. Davies MJ, et al. "Management of Hyperglycaemia in Type 2 Diabetes, 2022. A Consensus Report by the ADA and the EASD." Diabetes Care. 2022. https://diabetesjournals.org/care/article/45/11/2753/147494

6. Sherr JL, et al. "Nasal Glucagon for the Treatment of Severe Hypoglycemia." New England Journal of Medicine. 2019. https://www.nejm.org/doi/10.1056/NEJMoa1901448

7. American Diabetes Association. "Hypoglycemia (Low Blood Glucose) Treatment Overview." https://www.diabetes.org/living-with-diabetes/treatment-and-care/low-blood-glucose

8. Pratley RE, et al. "Tirzepatide versus insulin degludec in insulin-naive type 2 diabetes: SURPASS-3." New England Journal of Medicine. 2021. https://www.nejm.org/doi/10.1056/NEJMoa2107519